Therapeutic Peptides List 2026

Therapeutic Peptides List 2026. Popular therapeutic peptides in 2026, FDA-approved peptide drugs, and the peptide therapeutics pipeline researchers are watching. Key Takeaways Over 80 peptide drugs are FDA-approved worldwide and 170+ are in active clinical development — the fastest-growing drug class in pharma Therapeutic peptides cover tissue repair, metabolic, cognitive, immune, and mitochondrial categories — each with distinct mechanisms and research applications BPC-157, TB-500, and Thymosin Alpha-1 returned to Category 1 compounding status in February 2026 after the HHS reclassification Next-gen metabolic peptides like Retatrutide (triple agonist) showed up to 24.2% body weight reduction in Phase 2 — the highest ever recorded The global peptide therapeutics market exceeded $140 billion in 2025 and is projected to nearly double by 2033 Therapeutic peptides are short amino acid chains (2-50 residues) used in clinical research and approved medicine. Over 80 are FDA-approved, and more than 170 are in active clinical trials right now. This therapeutic peptides list breaks down every major compound by category — what it does, where the research stands, and which ones are available for research use. It covers the most popular therapeutic peptides 2026 researchers are tracking, the top selling research peptides and trending peptide brands of 2025-2026, the newest peptides entering the FDA approval pipeline, regenerative peptides spanning wound healing, musculoskeletal and CNS clinical trials, and the legal peptides currently sold for laboratory use. For a narrower body-composition and symptom framework, see our best peptides for menopause guide. For a broader overview of all peptides organized by mechanism (including non-therapeutic research compounds), see our complete list of peptides and what they do . For readers looking specifically for an FDA approved peptide drugs list 2026 or a list of FDA-approved peptides 2026 , this guide summarizes the major categories, while our dedicated FDA approved peptides list 2026 page provides the deeper drug-by-drug regulatory table. For research-use-only compounds that are not approved therapeutics, use our best grey market peptide vendors list to compare supplier verification, COA quality, and payment risk separately from the clinical evidence discussed here. BPC-157 (Body Protection Compound) BPC-157 is a 15-amino-acid peptide originally isolated from human gastric juice. It's one of the most extensively researched therapeutic peptides for tissue repair, with published studies documenting interactions with angiogenesis, growth factor, and anti-inflammatory pathways. Primary research: Tendon, ligament, and gastrointestinal tissue repair Mechanism: Promotes angiogenesis (new blood vessel formation) and upregulates growth factor expression Regulatory status: Not FDA-approved. Returned to Category 1 compounding status in February 2026 Published literature: Extensive preclinical data across wound healing, gut protection, and neuroprotective models BPC-157 is frequently studied alongside TB-500 for combined tissue repair protocols. For a detailed mechanistic comparison, see our BPC-157 vs TB-500 research guide . If you are calculating a combined research vial, use the BPC-157 TB-500 blend dosage calculator . For the full BPC-157 FDA approval status 2026 — including the RFK Jr reclassification announcement and the July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting — see our dedicated regulatory breakdown. TB-500 (Thymosin Beta-4) TB-500 is a synthetic version of Thymosin Beta-4, a naturally occurring peptide involved in cell migration and tissue regeneration. Research documents its role in actin regulation — the protein that controls cell structure and movement. Primary research: Soft tissue repair, inflammation, and cell migration Mechanism: Sequesters G-actin monomers and promotes lamellipodium formation for cellular mobility to injury sites Regulatory status: Not FDA-approved. Returned to Category 1 compounding status in February 2026 Published literature: Extensive veterinary medicine literature plus preclinical studies on muscle, tendon, and cardiac tissue For the regulatory timeline — including the February 2026 reclassification and current compounding eligibility — see our TB-500 FDA approval status 2026 breakdown. Retatrutide (Triple Agonist) Retatrutide (LY3437943) is Eli Lilly's investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 clinical trial data published in the New England Journal of Medicine showed up to 24.2% body weight reduction at 48 weeks — the highest ever reported in any obesity clinical trial. Primary research: Obesity, type 2 diabetes, metabolic syndrome Mechanism: Simultaneous activation of GLP-1 (appetite suppression), GIP (insulin sensitization), and glucagon (fat oxidation) receptors Regulatory status: Investigational. Phase 3 TRIUMPH program results expected in 2026 Retatrutide legal status 2026: Not FDA-approved in any country; available for laboratory research use only Key data: 24.2% weight loss at 48 weeks (Phase 2), with Phase 3 including 4 mg maintenance dose alongside 9 mg and 12 mg For the full retatrutide approval status 2026 — including the Eli Lilly Phase 3 timeline, EMA approval status, retatrutide availability across countries (including USA and Europe outside clinical trials), compounded retatrutide availability, retatrutide pricing, and where research-grade vendors like Core Peptides and Paradigm Peptides fit — see our dedicated regulatory breakdown. Tirzepatide (Dual GIP/GLP-1 Agonist) Tirzepatide is a dual GIP/GLP-1 receptor agonist FDA-approved as Mounjaro (type 2 diabetes, 2022) and Zepbound (obesity, 2023). It's one of the FDA approved peptides for weight loss 2026, alongside semaglutide (Wegovy) and liraglutide (Saxenda), and represents the current standard for next-generation incretin-based therapies, with clinical data showing superior weight loss compared to single-agonist GLP-1 drugs. For the full landscape of peptides for diabetes treatment — including all six FDA-approved GLP-1 agonists, tirzepatide, pramlintide, and the investigational triple agonist retatrutide — see our dedicated diabetes peptides guide. Primary research: Type 2 diabetes, obesity, metabolic disease Mechanism: Dual activation of GIP and GLP-1 receptors for enhanced metabolic effects Regulatory status: FDA-approved (Mounjaro 2022, Zepbound 2023) Key data: Up to 22.5% weight loss in SURMOUNT trials; expanding into heart failure, MASH, and sleep apnea indications Tesamorelin (GHRH Analog) Tesamorelin is a growth hormone-releasing hormone (GHRH) analog with FDA orphan drug designation. Approved as Egrifta for HIV-associated lipodystrophy, it's also researched for visceral fat reduction and cognitive function in broader populations. Primary research: Visceral fat reduction, lipodystrophy, cognitive function Mechanism: Stimulates pituitary growth hormone release via GHRH receptor activation Regulatory status: FDA-approved (Egrifta) for HIV-associated lipodystrophy Key data: Demonstrated significant visceral adipose tissue reduction and improved cognitive scores in published trials GHK-Cu (Copper Peptide) GHK-Cu is a naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine. Its levels decline with age, and research focuses on wound healing, collagen synthesis, and anti-inflammatory pathways. Primary research: Wound healing, skin regeneration, hair follicle stimulation Mechanism: Delivers copper to target tissues, upregulates collagen and glycosaminoglycan synthesis, and modulates inflammatory pathways Regulatory status: Not FDA-approved as a drug. Widely used in cosmetic skincare formulations. Published literature: Documented antioxidant, anti-inflammatory, and tissue remodeling properties across multiple studies For the full regulatory picture, see our GHK-Cu FDA approval status guide. CJC-1295 and Ipamorelin (Growth Hormone Secretagogues) CJC-1295 is a GHRH analog with an extended half-life, and Ipamorelin is a selective growth hormone secretagogue. They're frequently researched together — CJC-1295 provides sustained GH release while Ipamorelin adds a selective pulsatile GH spike with minimal cortisol or prolactin effects. Primary research: Growth hormone optimization, body composition, recovery Mechanism: CJC-1295 activates GHRH receptors for sustained GH elevation; Ipamorelin selectively activates ghrelin receptors for clean GH pulses Regulatory status: Not FDA-approved. Both returned to Category 1 compounding status in February 2026 Key advantage: Ipamorelin's selectivity means minimal appetite, cortisol, and prolactin side effects compared to older secretagogues like GHRP-6 For a detailed breakdown of these two compounds, see our CJC-1295 vs Ipamorelin comparison . For the current Ipamorelin FDA approval status — including the 2026 compounding reclassification — see our dedicated regulatory page. Selank and Semax (Cognitive Peptides) Selank and Semax are two of the most established therapeutic peptides for cognitive and neurological research. Both are clinically used in Russia and have extensive published literature. Selank A synthetic tuftsin-derived peptide with anxiolytic properties and no sedative effects. Research documents GABA modulation, BDNF expression, and immunomodulatory activity. Primary research: Anxiety, cognitive enhancement, immune modulation Mechanism: Enhances GABA signaling, increases BDNF expression, modulates enkephalin metabolism Administration: Intranasal for rapid absorption Regulatory status: Returned to Category 1 compounding status in February 2026 For the full research breakdown, see our Selank peptide benefits guide. Semax An ACTH(4-10) analog originally developed for stroke recovery research. Documented interactions with BDNF pathways make it one of the most studied nootropic peptides. Primary research: Memory, focus, neuroprotection, stroke recovery Mechanism: Upregulates BDNF and NGF expression, modulates dopaminergic and serotonergic systems Administration: Intranasal Regulatory status: Returned to Category 1 compounding status in February 2026 KPV (Anti-Inflammatory Peptide) KPV is a tripeptide (Lys-Pro-Val) derived from alpha-melanocyte stimulating hormone (α-MSH). Research has focused on its anti-inflammatory effects — particularly in gut tissue and skin inflammation models — without causing immunosuppression. Primary research: Gut inflammation, skin barrier function, general anti-inflammatory Mechanism: Inhibits NF-κB inflammatory signaling pathway activation Key advantage: Anti-inflammatory effects without immunosuppression — a critical distinction from corticosteroids Regulatory status: Not FDA-approved. Research compound. For the full research guide, see our KPV peptide guide . PT-141 (Bremelanotide) PT-141 is a melanocortin receptor agonist. The FDA-approved version (Vyleesi) was approved in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women — making it one of the few therapeutic peptides approved specifically for sexual health. Primary research: Sexual dysfunction, melanocortin receptor activation Mechanism: Activates melanocortin-4 receptors (MC4R) in the central nervous system, distinct from PDE5 inhibitors like sildenafil Regulatory status: FDA-approved as Vyleesi (2019) for HSDD in premenopausal women Key distinction: Works through CNS melanocortin pathways rather than vascular mechanisms SS-31 / Elamipretide (Mitochondrial Peptide) SS-31 (Elamipretide) is a synthetic tetrapeptide that selectively targets the inner mitochondrial membrane by binding cardiolipin. It became the first mitochondria-targeted peptide to receive FDA approval (as Forzinity for Barth syndrome). Primary research: Mitochondrial dysfunction, Barth syndrome, heart failure, age-related mitochondrial decline Mechanism: Binds cardiolipin in the inner mitochondrial membrane, stabilizing electron transport chain function and reducing reactive oxygen species Regulatory status: FDA-approved (Forzinity) for Barth syndrome. Ongoing trials in heart failure and primary mitochondrial myopathy. Key significance: Proof-of-concept that mitochondria-targeted peptides can reach FDA approval For the complete regulatory timeline, see our Elamipretide FDA approval status guide. MOTS-c (Mitochondrial-Derived Peptide) MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial genome. Research documents its role in metabolic homeostasis, insulin sensitivity, and exercise capacity — making it one of the most studied mitochondrial-derived peptides (MDPs). Primary research: Insulin sensitivity, exercise capacity, metabolic regulation Mechanism: Activates AMPK pathway, regulates folate-methionine metabolism, and modulates nuclear gene expression from the mitochondria Regulatory status: Not FDA-approved. Active research compound. Key data: Published studies show improved glucose metabolism and exercise performance markers For current clinical trial data, see our MOTS-c clinical trials status 2026 breakdown. Humanin (Cytoprotective Peptide) Humanin is a 24-amino-acid mitochondrial-derived peptide with documented cytoprotective and anti-apoptotic properties. It was first discovered in surviving neurons of Alzheimer's disease patients, sparking research into neuroprotection and age-related cellular pathways. Primary research: Neuroprotection, cellular survival, age-related cognitive decline Mechanism: Activates STAT3 signaling, inhibits Bax-mediated apoptosis, and interacts with IGFBP-3 Regulatory status: Not FDA-approved. Research compound. Key significance: One of the first mitochondrial-derived peptides identified — opened the field of MDP research DSIP (Delta Sleep Inducing Peptide) DSIP is a 9-amino-acid neuropeptide originally isolated from rabbit brain tissue during induced sleep. Research focuses on its role in sleep architecture regulation, circadian rhythm modulation, and stress response pathways. Primary research: Sleep regulation, circadian rhythm, stress response Mechanism: Modulates sleep spindle activity and interacts with multiple neurotransmitter systems including GABA, serotonin, and glutamate Regulatory status: Not FDA-approved. Research compound. Published literature: Documented effects on sleep architecture and cortisol modulation in published studies Therapeutic Peptides Comparison Table Peptide Category FDA Status Primary Research Application BPC-157 Tissue Repair Category 1 (2026) Tendon, ligament, GI repair TB-500 Tissue Repair Category 1 (2026) Soft tissue, cell migration Retatrutide Metabolic Phase 3 trials Obesity, metabolic syndrome Tirzepatide Metabolic FDA-approved Type 2 diabetes, obesity Tesamorelin Metabolic / GH FDA-approved Lipodystrophy, visceral fat GHK-Cu Skin / Repair Not approved Wound healing, collagen CJC-1295 GH Secretagogue Category 1 (2026) Growth hormone release Ipamorelin GH Secretagogue Category 1 (2026) Selective GH release Selank Cognitive Category 1 (2026) Anxiety, GABA modulation Semax Cognitive Category 1 (2026) Memory, BDNF pathways KPV Anti-inflammatory Not approved Gut inflammation, skin PT-141 Neurological FDA-approved Sexual health (HSDD) SS-31 Mitochondrial FDA-approved Barth syndrome, mito dysfunction MOTS-c Mitochondrial Not approved Insulin sensitivity, exercise Humanin Cytoprotective Not approved Neuroprotection, aging DSIP Neurological Not approved Sleep regulation 2026 FDA Peptide Reclassification On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides placed on the FDA's Category 2 restricted list in late 2023 would return to Category 1 status — making them eligible for routine compounding by 503A pharmacies again. Peptides returning to Category 1 include BPC-157, TB-500, Thymosin Alpha-1, CJC-1295, Ipamorelin, AOD-9604, Selank, and Semax. This is a compounding regulation change, not FDA drug approval — these compounds still require physician oversight and are not approved treatments. For a complete breakdown of which peptides are FDA-approved drugs vs. compounding-eligible research compounds, see our FDA approved peptides list 2026 . Frequently Asked Questions What are therapeutic peptides? Therapeutic peptides are short amino acid chains (2-50 residues) used in clinical medicine and research. Over 80 are FDA-approved worldwide for conditions ranging from diabetes and obesity to cancer and rare diseases. Many more are in active clinical trials or used as research compounds. What is the most prescribed therapeutic peptide? Semaglutide (Ozempic/Wegovy) is currently the most prescribed therapeutic peptide globally. The GLP-1 agonist class dominates peptide drug revenue, with tirzepatide (Mounjaro/Zepbound) rapidly gaining market share as a dual-agonist alternative. What is the difference between therapeutic peptides and research peptides? Therapeutic peptides have FDA approval for specific medical indications and are prescribed by physicians. Research peptides are sold for laboratory use and have not received regulatory approval for human treatment. Compounds like BPC-157 and TB-500 have extensive published research but are not FDA-approved drugs. Which therapeutic peptides were reclassified in 2026? In February 2026, approximately 14 peptides returned to Category 1 compounding status after being restricted in late 2023. These include BPC-157, TB-500, CJC-1295, Ipamorelin, AOD-9604, Selank, Semax, and Thymosin Alpha-1. This allows 503A pharmacy compounding but does not constitute FDA drug approval. What therapeutic peptides are used for tissue repair? BPC-157 and TB-500 are the most researched therapeutic peptides for tissue repair. BPC-157 focuses on tendon, ligament, and GI tissue through angiogenesis pathways. TB-500 targets soft tissue repair through actin regulation and cell migration. They're frequently studied together. For a detailed comparison, see our BPC-157 vs TB-500 guide . Are therapeutic peptides safe? FDA-approved therapeutic peptides have undergone extensive clinical trials with documented safety profiles. Research-stage peptides have varying levels of safety data. Quality sourcing, third-party testing, and physician oversight matter significantly regardless of category. See our guide on research peptide safety for evaluation criteria. References U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs database. accessdata.fda.gov U.S. Food and Drug Administration. Novel Drug Approvals. fda.gov Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med . 2021;384:989. PubMed Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med . 2022;387:205-216. PubMed Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des . 2011;17(16):1612-32. PubMed Goldstein AL, et al. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med . 2005;11(9):421-9. PubMed Falutz J, et al. Effects of tesamorelin in HIV-infected patients with excess abdominal fat: pooled analysis of two Phase 3 trials. J Clin Endocrinol Metab . 2010;95(9):4291-304. PubMed Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide. Int J Mol Sci . 2018;19(7):1987. PubMed ClinicalTrials.gov. National Library of Medicine clinical trials database — peptide research. clinicaltrials.gov Disclaimer: This article compiles published clinical and regulatory data for informational and educational purposes only. It does not constitute medical advice. Some compounds discussed are investigational and not approved by the FDA. All research peptides referenced are intended for laboratory use only. Not for human consumption. Always consult a qualified healthcare provider before starting any peptide therapy. Related reading: Investigational Peptide Drugs: Diabetes & Obesity Review PeptideStack page context: visitors can use the header navigation to reach the product catalog, blog, calculators, supplier pages, discount-code pages, contact page, legal policies, shipping policy, refund policy, privacy policy, terms, and research disclaimer. The site is organized around research peptide education, supplier transparency, product comparison, vendor review content, discount-code tracking, and calculator tools for reconstitution or unit conversion research planning. PeptideStack separates research-use-only peptide information from FDA-approved medication and licensed telehealth pathways. Research peptide pages are informational and are not medical advice, prescription guidance, dosing instructions, treatment recommendations, or instructions for human consumption. Many pages include affiliate disclosures because PeptideStack may earn a commission when visitors click external supplier or telehealth links. That commission does not change the price paid by visitors and does not mean PeptideStack manufactures, sells, distributes, compounds, or ships peptides or medications. Supplier and product pages should be evaluated for third-party testing, batch-specific certificates of analysis, named laboratory verification, transparent pricing, realistic delivery expectations, payment security, refund policies, support quality, and consistent research-use-only labeling. Blog pages connect related guides, comparison articles, FDA approval status explainers, safety context, legality resources, product pages, vendor reviews, and calculator tools so visitors can keep researching without relying on a single supplier claim. Calculator pages are educational tools for laboratory planning and should be cross-checked against professional protocols, institutional requirements, and applicable laws. Legal and disclaimer pages explain the boundaries of PeptideStack content and the responsibility of visitors who evaluate third-party vendors. The rendered interface may add interactive details such as mobile navigation labels, product tabs, share buttons, related article cards, disclosure boxes, call-to-action buttons, vendor selectors, copy-code controls, email-code forms, footer navigation, and status labels. The static HTML fallback includes this context so the same page purpose is understandable before the JavaScript application finishes loading. Visitors should treat PeptideStack as a research and comparison starting point. Final supplier evaluation should include direct review of the external vendor website, current product availability, checkout terms, applicable laws, institutional requirements, and any third-party laboratory documentation available for the exact product or batch being considered. Footer resources repeat important sitewide context: PeptideStack is independent, affiliate-supported, research-focused, and not a pharmacy or manufacturer. Pages may include links to the iOS app, calculators, blog hubs, product hubs, supplier comparisons, support contact, and policy documents. This repeated context is intentionally available in the raw HTML for crawlers that inspect a page before executing the React bundle. Raw HTML also includes page summaries for mobile crawlers using JavaScript rendering, desktop crawlers comparing source to rendered output, accessibility tools, and no-script visitors. The fallback is replaced by the React app in normal browsers but keeps the source document aligned with the visible page topic. This fallback keeps source HTML and rendered HTML closer for crawl diagnostics and SEO audits across crawled pages, routes, reports, and recrawls.